Learn More
Cannabidiol (CBD), a nonpsychoactive cannabinoid of Cannabis, was given to 5 patients with dystonic movement disorders in a preliminary open pilot study. Oral doses of CBD rising from 100 to 600 mg/day over a 6 week period were administered along with standard medication. Dose-related improvement in dystonia was observed in all patients and ranged from 20(More)
We evaluated the current status of 131 patients with idiopathic parkinsonism who were receiving levodopa therapy. The residual parkinsonian symptoms and signs were tabulated, as were the adverse effects from medication. Response to therapy was correlated with duration of the disease and with duration of treatment. Patients with on-off or wearing-off effects(More)
Based on encouraging preliminary findings, cannabidiol (CBD), a major nonpsychotropic constituent of Cannabis, was evaluated for symptomatic efficacy and safety in 15 neuroleptic-free patients with Huntington's Disease (HD). The effects of oral CBD (10 mg/kg/day for 6 weeks) and placebo (sesame oil for 6 weeks) were ascertained weekly under a double-blind,(More)
The dopamine agonist, bromocriptine, produced either inhibition or stimulation of motor behaviour in rats depending upon the dose and time after administration. Stimulation of motor activity occurred only with high doses after a 1-2 h delay. Both inhibition and stimulation were associated with decreased turnover of dopamine in the brain. Release of(More)
One pair of rat adrenals was found to contain 100–200 ng of dopamine (DA), the molar concentration ratio of DA to adrenaline + noradrenaline being about 0.005. After inhibition of tyrosine hydroxylase DA decreased exponentially, with a half life of 1.35 h. Insulin and the ganglionic blocking agent chlorisondamine caused within 90 min an increase in adrenal(More)
Endogenous levels of dopamine (DA) were measured in rat salivary glands and hearts using a new sensitive method. In these organs normally about 15 ng/g DA was found. After inhibition of the tyrosine hydroxylase or after treatment with 6-hydroxydopamine, the DA content of the organs decreased. Electrical stimulation of the cervical sympathetic rapidly(More)
To test possible biochemical mechanisms by which L-tryptophan may reverse mental side effects of levodopa therapy in parkinsonism we administered levodopa, 250 mg per kilogram intraperitoneally, alone and with L-tryptophan, 500 mg per kilogram intraperitoneally, to rats pretreated with the peripheral dopa decarboxylase inhibitor, carbidopa (25 mg per(More)